LMNA and cardiomyopathy: Previously, microarray analysis in a mouse model harboring the Lmna mutation (LmnaH222P/H222P) for Emery-Dreifuss muscular dystrophy and cardiomyopathy showed that there was over-activation of mitogen-activated protein kinase 3/1 (ERK1/2) and mechanistic targeting of rapamycin kinase (mTOR) pathways7–9,17,18.